Wexford Capital: R3 Vascular Inc. Completes Series A Financing Round and New Chief Executive Officer
The company reports the proceeds will support the company's clinical trial work in developing a next generation of below-the-knee (BTK) interventional therapies for PAD.
Read full article »
Wexford Capital is an employee owned hedge fund sponsor.
Read more